Meadow Creek Wealth Advisors LLC Sells 1,800 Shares of Johnson & Johnson (NYSE:JNJ)

Meadow Creek Wealth Advisors LLC lowered its position in Johnson & Johnson (NYSE:JNJ) by 23.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,903 shares of the company’s stock after selling 1,800 shares during the quarter. Meadow Creek Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $863,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bernardo Wealth Planning LLC grew its holdings in shares of Johnson & Johnson by 17.6% during the fourth quarter. Bernardo Wealth Planning LLC now owns 7,017 shares of the company’s stock worth $1,100,000 after purchasing an additional 1,052 shares in the last quarter. Turtle Creek Wealth Advisors LLC bought a new stake in Johnson & Johnson during the fourth quarter valued at approximately $430,000. B.O.S.S. Retirement Advisors LLC grew its stake in Johnson & Johnson by 5.1% in the 4th quarter. B.O.S.S. Retirement Advisors LLC now owns 21,378 shares of the company’s stock worth $3,351,000 after buying an additional 1,045 shares in the last quarter. Sequoia Financial Advisors LLC increased its holdings in shares of Johnson & Johnson by 71.7% in the 4th quarter. Sequoia Financial Advisors LLC now owns 92,337 shares of the company’s stock worth $14,473,000 after buying an additional 38,559 shares during the last quarter. Finally, Williams & Novak LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter worth $252,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.4 %

JNJ traded up $0.62 during midday trading on Thursday, reaching $159.10. 7,237,481 shares of the company’s stock traded hands, compared to its average volume of 7,355,802. The stock has a market capitalization of $382.90 billion, a price-to-earnings ratio of 9.90, a P/E/G ratio of 2.63 and a beta of 0.52. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.39. The firm has a fifty day moving average of $151.88 and a two-hundred day moving average of $153.10. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business had revenue of $22.45 billion for the quarter, compared to analysts’ expectations of $22.33 billion. During the same quarter in the previous year, the business posted $2.80 earnings per share. The firm’s revenue for the quarter was up 4.3% compared to the same quarter last year. On average, equities analysts anticipate that Johnson & Johnson will post 10.07 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.12%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s payout ratio is currently 30.92%.

Analysts Set New Price Targets

A number of research firms have weighed in on JNJ. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Monday, August 5th. TD Securities dropped their target price on Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. The Goldman Sachs Group decreased their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research note on Friday, July 19th. Morgan Stanley increased their target price on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a report on Thursday, July 18th. Finally, Sanford C. Bernstein boosted their price target on shares of Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Seven investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $173.21.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.